Immorta Bio Inc. was named to the 2026–27 Life Sciences cohort of Endless Frontier Labs at New York University Stern School of Business after a multi-stage evaluation of the company’s science, development strategy and commercial potential.
Immorta Bio is developing two complementary therapeutic platforms: SenoMune, a senolytic immunotherapy platform designed to restore immune-mediated elimination of senescent cells, and StemCellRevivify, a regenerative cell-therapy platform intended to restore youthful cellular function and regenerative capacity.
The nine-month Endless Frontier Labs program offers startups access to entrepreneurs, scientists, investors and Stern MBA students, and the company expects to use the program as it advances from preclinical development toward human clinical execution and to expand strategic and institutional relationships.
The company claims its platforms form a strategy to apply youthful biology across oncology, organ regeneration and diseases of aging.
